Page last updated on March 28, 2025
Enveric Biosciences, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-03-28 17:19:42 EDT.
Filings
10-K filed on 2025-03-28
Enveric Biosciences, Inc. filed a 10-K at 2025-03-28 17:19:42 EDT
Accession Number: 0001641172-25-001296
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
Item 1C. Cybersecurity Cybersecurity Risk Management and Strategy We have established certain processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management strategy. Such processes include physical, procedural and technical safeguards, response methods, regular tests on our systems, and routine review of our processes to identify risks and enhance our practices. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. We engage certain external parties, including consultants and computer security firms to enhance our cybersecurity oversight and provide monthly trainings to our employees. We consider the internal risk oversight programs of third-party service providers before engaging them in order to help protect our company from any related vulnerabilities. At this time, we are not aware of any material cybersecurity incidents that have impacted the Company. For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report. Governance Our board of directors is involved in the oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our board of directors has delegated authority to the Audit Committee to serve as the cybersecurity oversight body, which works with the chief financial officer to assess and respond to cybersecurity threats. The chief financial officer meets with the third-party vendors regularly to discuss any issues and updates related to the Company’s information technology environment and reports to the Audit Committee on a quarterly basis.
Company Information
Name | Enveric Biosciences, Inc. |
CIK | 0000890821 |
SIC Description | Pharmaceutical Preparations |
Ticker | ENVB - Nasdaq |
Website | |
Category | Non-accelerated filer Smaller reporting company |
Fiscal Year End | December 30 |